US FDA flags manufacturing and data integrity lapses at Dabur India plant
The U.S. Food and Drug Administration has just delivered a scathing Form 483 to Dabur India, detailing egregious manufacturing and data integrity lapses at one of its key facilities near Ghaziabad. Inspectors reportedly found a live bird, extensive bird droppings, and "unidentified black substances" in storage areas, directly compromising the sterile environment required for consumer health products. This immediate flag raises serious concerns about the safety and efficacy of products destined for the crucial U.S. market, particularly those marketed under its rapidly expanding Ayurvedic portfolio.













